Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response

We conducted a prospective evaluation of cord blood (CB)–derived adoptive cell therapy, after salvage chemotherapy, for patients with advanced myeloid malignancies and poor prognosis. Previously, we reported safety, feasibility, and preliminary efficacy of this approach. We present updated results i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Chaekal, Ok-kyong, Scaradavou, Andromachi, Masson Frenet, Emeline, Albano, Maria S., Cushing, Melissa, Desai, Pinkal, Dobrila, Ludy, Gergis, Usama, Guarneri, Danielle, Hsu, Jing-Mei, Lee, Sangmin, Mayer, Sebastian A., Phillips, Adrienne A., Orfali, Nina, Ritchie, Ellen K., Roboz, Gail J., Romeo, Cynthia, Samuel, Michael S., Shore, Tsiporah, van Besien, Koen
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594383/
https://ncbi.nlm.nih.gov/pubmed/33091124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002805
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares